The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study.

scientific article published on January 2013

The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study. is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1016410494
P356DOI10.1186/AR4383
P932PMC publication ID3978999
P698PubMed publication ID24246100
P5875ResearchGate publication ID258641067

P50authorDanny LiewQ38326593
Vivek ThakkarQ56941027
Peter NashQ63367206
P2093author name stringSusanna M Proudman
Wendy Stevens
David Prior
Jane Zochling
Mandana Nikpour
Joanne Sahhar
Eli Gabbay
Janet Roddy
Maureen Rischmueller
Peter Youssef
Susan Lester
Jennifer G Walker
P2860cites workStandardisation of the single-breath determination of carbon monoxide uptake in the lungQ28275504
N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control studyQ30463476
Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trialQ33156379
Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT studyQ33834751
The pathogenesis of systemic sclerosisQ34150716
Criteria for the classification of early systemic sclerosis.Q34317138
ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American CollQ34977467
Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the InQ34999923
Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approachQ35552142
Changes in causes of death in systemic sclerosis, 1972-2002Q35954516
Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and IrelandQ37085266
Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic reviewQ37424577
Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS groupQ37643044
Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria CommitteeQ39513167
Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvementQ39641547
Tricuspid annular plane systolic excursion is a robust outcome measure in systemic sclerosis-associated pulmonary arterial hypertension.Q39701731
Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertensionQ40547439
Comparison of brain natriuretic peptide (BNP) and NT-proBNP in screening for pulmonary arterial hypertension in patients with systemic sclerosisQ42969084
Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafilQ43218254
Pulmonary arterial hypertension associated with systemic sclerosis in the Czech RepublicQ43838385
Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studiesQ44577909
Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trialQ45069603
N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockersQ48117072
Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertensionQ48550363
NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) echocardiographic substudyQ48631855
Is pulmonary arterial hypertension really a late complication of systemic sclerosis?Q51131925
Preliminary criteria for the classification of systemic sclerosis (scleroderma)Q54165663
Screening for pulmonary arterial hypertension in patients with systemic sclerosis: Clinical characteristics at diagnosis and long-term survivalQ56978019
The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in FranceQ56978153
Early detection of pulmonary arterial hypertension in systemic sclerosis: A French nationwide prospective multicenter studyQ56978308
Connective Tissue Disease–associated Pulmonary Arterial Hypertension in the Modern Treatment EraQ60168168
Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosisQ79782391
High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosisQ80419679
N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF studyQ80428291
Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterizationQ80510899
Usefulness of echocardiography in the identification of an excessive increase in pulmonary arterial pressure in patients with systemic sclerosisQ83299938
Echo Doppler predictors of pulmonary artery hypertension in patients with systemic sclerosisQ84926020
P433issue6
P921main subjectarterial hypertensionQ41861
brain natriuretic peptideQ66360952
P304page(s)R193
P577publication date2013-01-01
P1433published inArthritis Research and TherapyQ15757229
P1476titleThe inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study
P478volume15

Reverse relations

cites work (P2860)
Q35096375A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis
Q48115705A systematic review of the epidemiology, disease characteristics and management of systemic sclerosis in Australian adults
Q38771824Biomarkers in Scleroderma: Progressing from Association to Clinical Utility
Q33582869Cardiovascular Comorbidity in Inflammatory Rheumatological Conditions.
Q91948784Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline
Q38271027Early detection of pulmonary arterial hypertension
Q33801248High sensitivity and negative predictive value of the DETECT algorithm for an early diagnosis of pulmonary arterial hypertension in systemic sclerosis: application in a single center.
Q50097908Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group.
Q90966606Major lung complications of systemic sclerosis
Q40153822Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model
Q30490484Multicentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocol
Q38367248Prospects for improving outcomes in systemic sclerosis-related pulmonary hypertension.
Q92534334Pulmonary Arterial Hypertension In Systemic Sclerosis: Challenges In Diagnosis, Screening And Treatment
Q92133612Screening strategies for pulmonary arterial hypertension
Q38663003Unmet Needs in the Pathogenesis and Treatment of Cardiovascular Comorbidities in Chronic Inflammatory Diseases.
Q36234697Use of ECG and Other Simple Non-Invasive Tools to Assess Pulmonary Hypertension

Search more.